EXAGEN Files 8-K on Financial Condition, Operations

TL;DR

**EXAGEN just dropped an 8-K about their financials, so expect new info soon.**

AI Summary

EXAGEN INC. filed an 8-K on January 8, 2024, reporting an event that occurred on January 7, 2024, related to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'. This filing indicates that the company, trading under the symbol XGN on The Nasdaq Global Market, is providing an update on its financial performance. For investors, this matters because it signals that new financial information is being disclosed, which could impact the stock's valuation and future prospects.

Why It Matters

This filing signals that EXAGEN INC. is disclosing new financial information, which could provide critical insights into the company's performance and future outlook for investors.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the underlying financial information it refers to could contain significant risks or opportunities.

Analyst Insight

A smart investor would monitor for the actual financial statements and results of operations that this 8-K foreshadows, as they will contain the substantive information impacting EXAGEN INC.'s valuation.

Key Numbers

• $0.001 — par value per share (par value of EXAGEN INC.'s Common Stock)

Key Players & Entities

• EXAGEN INC. (company) — registrant filing the 8-K
• The Nasdaq Global Market (company) — exchange where EXAGEN's common stock is registered
• XGN (company) — trading symbol for EXAGEN INC.
• January 7, 2024 (date) — date of earliest event reported
• January 8, 2024 (date) — date the 8-K was filed
• $0.001 (dollar_amount) — par value per share of Common Stock

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share XGN The Nasdaq Global Mar

Filing Documents

• exdx-20240107.htm (8-K) — 29KB
• pressrelease-2023selectpre.htm (EX-99.1) — 15KB
• imagea.jpg (GRAPHIC) — 4KB
• 0001274737-24-000006.txt ( ) — 181KB
• exdx-20240107.xsd (EX-101.SCH) — 2KB
• exdx-20240107_lab.xml (EX-101.LAB) — 24KB
• exdx-20240107_pre.xml (EX-101.PRE) — 13KB
• exdx-20240107_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 7, 2024 , Exagen Inc. (the "Company") provided select preliminary unaudited financial information and results of operations for the year ended December 31, 2023, based on currently available information. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report. The preliminary unaudited financial data included in the press release has been prepared by, and is the responsibility of, our management. BDO USA, P.C. ("BDO") has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary unaudited financial information and results of operations. Accordingly, BDO does not express an opinion or any other form of assurance with respect thereto. The information furnished with Item 2.02 of this report, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filings under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EXAGEN INC. Date: January 8, 2024 By: /s/ Kamal Adawi Kamal Adawi Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR